New two-year data show that bimekizumab (Bimzelx) provides lasting disease control for people with moderate to severe hidradenitis suppurativa (HS)​. In clinical trials, more than 85 percent of people in the study maintained their treatment response over two years, and the amount of people with severe disease dropped from 87.4 percent to 20.4 percent​.

Bimekizumab was approved by the U.S. Food and Drug Administration (FDA) in November 2024 for the treatment of moderate to severe HS in adults. It works by blocking both interleukin (IL)-17A and IL-17F, two key proteins involved in HS.

The study tracked people who had completed 48 weeks of bimekizumab treatment and then continued in a long-term extension study. At the two-year mark, data showed:

• 86.9 percent of the people in the study maintained a 75 percent or greater improvement in HS symptoms.
• 83.4 percent remained flare-free during this period, meaning symptoms did not return.
• More than half (53.1 percent) were classified as having mild HS after two years, compared to none having mild HS at the start of the study.

The treatment also led to improved quality of life, with many participants reporting less pain, wound drainage, and discomfort.

As with any treatment, bimekizumab may cause side effects. The most commonly reported side effects for people with HS include upper respiratory infections, headache, and fungal infections. Serious side effects include increased risk of infections, which is a common concern with biologic medications that affect the immune system.

The First IL-17A and IL-17F Inhibitor for HS

HS is a painful, chronic condition with limited treatment options, and many people experience persistent flare-ups despite standard therapies. Bimekizumab is the first approved therapy for HS that blocks both IL-17A and IL-17F, offering a new approach to reducing inflammation and disease severity.

If you’re experiencing frequent HS flare-ups or your current treatment isn’t providing enough relief, it may be helpful to talk to your dermatologist or healthcare provider about alternative options.

Learn more about the range of treatment options available for HS.

Find Your Team

On myHSteam, the social network for people living with hidradenitis suppurativa, members share experiences and support one another.

Have you tried biologic treatments for HS? What has your experience been like? Share your thoughts in the comments below, post to your Activities feed, or connect with like-minded members in Groups.